Lyra Therapeutics (LYRA) Assets Average (2020 - 2025)

Lyra Therapeutics has reported Assets Average for 6 years, with the latest figure at $39.9 million in Q4 2025.

• On a quarterly basis, Assets Average fell 44.99% year-over-year to $39.9 million in Q4 2025; TTM through Dec 2025 was $39.9 million, a 44.99% decrease from a year earlier, with the FY2025 full-year figure at $51.2 million, down 50.97% from the prior year.
• Assets Average was $39.9 million for Q4 2025 at Lyra Therapeutics, down from $48.1 million in the prior quarter.
• The five-year high for Assets Average was $142.1 million in Q1 2024, with the low at $39.9 million in Q4 2025.
• Average Assets Average over 5 years is $87.7 million, with a median of $81.8 million recorded in 2021.
• The sharpest annual moves came in 2021 and 2025: Assets Average jumped 175.88% in 2021, then tumbled 56.83% in 2025.
• Over 5 years, Assets Average stood at $61.3 million in 2021, then surged by 87.09% to $114.7 million in 2022, then increased by 14.71% to $131.6 million in 2023, then slumped by 44.86% to $72.6 million in 2024, then tumbled by 44.99% to $39.9 million in 2025.
• The last three Assets Average figures came in at $39.9 million (Q4 2025), $48.1 million (Q3 2025), and $54.4 million (Q2 2025), per Business Quant data.